Streetbeat News

SNES

SenesTech, Inc.

https://www.senestech.com

Industry

Chemicals - Specialty

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

Open

2.43

Mkt cap

2.3M

Volume

231K

High

2.43

P/E Ratio

0.02

52-wk high

9.80

Low

2.12

Div yield

N/A

52-wk low

1.90

SenesTech reported Q1 2024 GAAP EPS of $(0.36), missing the $(0.34) estimate, and sales of $415K, below the $429K estimate. Despite these misses, the losses and sales figures represent significant improvements over the same period last year, with losses decreasing by 96.98% and sales increasing by 78.11%.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:13 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. Processa Pharma led the gainers with a 31.2% increase, while Sunshine Biopharma experienced the largest drop among the losers, declining by 10.5%. The movements reflect varying market capitalizations and investor reactions to company-specific news or broader sector trends.

Portfolio Pulse from Benzinga Insights

April 25, 2024 | 12:06 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. PaxMedica (PXMD) led the gainers with a 110.9% increase, while Motus GI Holdings (MOTS) saw the largest decline at 39%. Other notable movers include Q32 Bio (QTTB), Cyclacel Pharmaceuticals (CYCCP), and Rani Therapeutics Holdings (RANI) among the gainers, and Monogram Orthopaedics (MGRM) and BioSig Technologies (BSGM) among the losers.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 4:31 pm

SenesTech, Inc. (NASDAQ:SNES) has signed a distribution agreement with Wilco Distributors for its fertility control products, Evolve and ContraPest, targeting the agriculture and professional rodent pest management market. This partnership aims to offer alternatives to traditional rodent control methods, focusing on reducing rodent fertility. The rodent pest control market, with over $1 billion in annual product sales, faces challenges from regulatory restrictions on poisons, highlighting the potential for SenesTech's solutions.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 1:10 pm

Health care stocks experienced significant movements in Thursday's intraday session. Monopar Therapeutics and Calidi Biotherapeutics led the gainers with over 75% increases in their stock prices, while Synaptogenix and Motus GI Holdings were among the top losers, with over 20% declines. Notably, Amylyx Pharma and SenesTech released their Q4 earnings, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:31 pm

SenesTech reported Q4 2023 GAAP EPS of $(9.54) and sales of $295K, missing the consensus estimate of $380K by 22.37%. This represents a 0.67% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 10:41 pm

The article lists companies scheduled to report their earnings on February 21, 2024, including their expected earnings per share and revenue. It covers a wide range of industries and includes both companies expected to report profits and losses.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 10:09 am

SenesTech (NASDAQ:SNES) is scheduled to release its quarterly earnings report on February 21, 2024, with an expected EPS of $-0.44. The company's past earnings performance shows a history of both beating and missing EPS estimates, with significant share price fluctuations following the announcements. Shares of SenesTech have declined 95.32% over the last 52 weeks, indicating a challenging period for the company. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 8:01 pm

In Thursday's after-market session, several healthcare stocks showed notable movements. Gainers included China Pharma Holding, SenesTech, Lucy Scientific Discovery, OneMedNet, Universe Pharmaceuticals, and Vaxxinity with increases ranging from 4.99% to 12.7%. Losers were led by Modular Medical, Adial Pharmaceuticals, Pacific Biosciences, Nuwellis, Perspective Therapeutics, and Onconova Therapeutics, with declines between 4.39% and 16.3%. Key financial updates were noted for Lucy Scientific Discovery, Modular Medical, and Pacific Biosciences.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 9:31 pm

SenesTech has entered into an exclusive distribution agreement with Q-chem to distribute its Evolve Soft Bait product in the Netherlands. This partnership aims to expand the reach of SenesTech's innovative rodent control solution in the European market.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 2:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.